Document is current
Any future updates will be listed below
-
Authors
Bounas, Andreas https://orcid.org/0000-0001-5995-6187
Kandyli, Anna
Katsifi, Gkikas https://orcid.org/0000-0002-3214-7416
Boumpa, Dimitrios https://orcid.org/0000-0002-9812-4671
Tektonidou, Maria G. https://orcid.org/0000-0003-2238-0975
Gazi, Sousana https://orcid.org/0000-0002-3151-2055
Kotrotsios, Anastasios https://orcid.org/0000-0003-0486-9179
Sakkas, Lazaros I. https://orcid.org/0000-0002-7670-3314
Georgiadis, Athanasios N. https://orcid.org/0000-0002-9561-6355
Settas, Loukas
Madia, Xenia https://orcid.org/0009-0001-1900-9924
Ignatiadi, Dimitra
Sfikakis, Petros P. https://orcid.org/0000-0001-5484-2930
-
Funding
Funding for this research was provided by:
Novartis Hellas
- License Information
-
More Information
Article History
Received: 3 October 2024
Accepted: 19 March 2025
First Online: 18 April 2025
Declarations
:
: A. Bounas: research grants, honorarium for educational activities and consultancy fees from Abbvie, Aenorasis, Amgen, Bausch Health, FARAN, Genesis Pharma, GSK, Janssen, MSD, Novartis, Pfizer, UCB; A. Kandyli: clinical trial investigator fees, honorarium for educational activities and consultancy fees from Vianex, Enorasis, Abbvie, Pfizer, UCB and SOBI; G. Katsifis: honorarium for educational activities and consultancy fees from Abbvie, Boehringer Ingelheim, Janssen, Galapagos, Genesis Pharma, MSD, Novartis, Pfizer and Viatris; D. Boumpas: clinical trial investigator fees, honorarium for educational activities and consultancy fees from Abbvie, AstraZeneca, GSK, Novartis, Enorasis and Lilly; M. G. Tektonidou: research grants, honorarium for educational activities and consultancy fees from GSK, UCB and Lilly; S. Gazi: clinical trial investigator fees, honorarium for educational activities and consultancy fees from Pfizer, Lilly, Faran, Elpen, Abbvie and UCB; A. Kotrotsios: clinical trial investigator fees and honorarium for educational activities from Vianex, Novartis, UCB, Amgen, Pfizer and Abbvie; L. I. Sakkas: congress support from Abbvie; A. N. Georgiadis: clinical trial investigator fees, honorarium for educational activities and consultancy fees from Faran and Aenorasis; L. Settas: clinical trial investigator fees, honorarium for educational activities and consultancy fees from PPD, Pfizer, Abbvie, Horizon, Faran, Amgen and Sanofi; X. Madia: employee of Novartis Hellas S.A.C.I.; D. Ignatiadi: employee of Novartis Hellas S.A.C.I.; P. P. Sfikakis: research grants and consultancy fees from Abbvie, Roche, Pfizer, Faran, Amgen, Janssen, Boehringer Ingelheim, Gilead, Actelion, Genesis Pharma, MSD, UCB, Enorasis, Lilly and Novartis.
: This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit .
